SecBot SecBot
PRESS-RELEASE ·Filed Mar 30, 2026

NMRA

Neumora Therapeutics, Inc.
MIXED
Impact 5/10
Horizonmonths Processed7mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ◆ Mixed

While cost discipline improved financials, the delay in NMRA-215 due to toxicology concerns introduces pipeline risk. Investors should monitor the Q2 2026 readouts for navacaprant and NMRA-898, which are key near-term catalysts. The strong cash position reduces near-term dilution risk.

DirectionMixed
Confidencehigh
Horizonmonths

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$1.93
T+0 close · Mar 30, 2026 · via day close
Latest settled
−21.76%
T+60 · $1.51
Vs SPY
−38.25%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 30 $1.93entry
  2. T+1 · 8mo ago +1.04%α −1.85% · $1.95
  3. T+5 · 7mo ago +10.36%α +6.06% · $2.13
  4. T+20 · 7mo ago +16.58%α +3.98% · $2.25
  5. T+60 · 5mo ago −21.76%α −38.25% · $1.51
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Neumora Therapeutics reported Q4 and full-year 2025 financial results with reduced R&D and G&A expenses, resulting in a narrower net loss compared to the prior year. The company highlighted clinical progress across its pipeline, including new Phase 1b data for NMRA-511 in Alzheimer’s agitation, full enrollment in the KOASTAL-2 and -3 trials for navacaprant, and advancement of NMRA-898 as the lead M4 program in schizophrenia. With $182.5 million in cash, Neumora expects to fund operations into Q3 2027.

Key Financial Metrics

EPS
$-1.45

Key Facts

  • Neumora reported $182.5 million in cash, cash equivalents, and marketable securities as of December 31, 2025.
  • R&D expenses decreased to $176.1 million in 2025 from $200.9 million in 2024, primarily due to reduced navacaprant-related costs.
  • Net loss for full-year 2025 was $236.9 million, down slightly from $243.8 million in 2024.
  • NMRA-511 showed a Cohen’s d effect size of 0.34 on CMAI total score and 0.51 on aggression sub-factor in a pre-specified Alzheimer’s agitation population.
  • KOASTAL-2 and -3 trials for navacaprant are fully enrolled, with topline data expected in Q2 2026.
  • NMRA-898 has been selected as the lead M4 program based on favorable Phase 1 pharmacokinetics and target engagement data.
  • A 13-week rat toxicology study for NMRA-215 revealed unexpected adverse findings in 5 of 142 animals; Neumora is repeating the study and delaying clinical initiation to Q1 2027.

Financial Impact

Reduced R&D spending by $24.8M YoY contributed to lower net loss. Cash runway extended into Q3 2027.

r&d_expensenet_losscash_runway

Risk Factors

  • Unexpected toxicology findings in NMRA-215 could signal safety issues or development challenges.
  • Clinical data for navacaprant and NMRA-511 remain upcoming; failure to meet endpoints could negatively impact valuation.
  • Biotech sentiment and financing conditions may affect future capital raising if extended runway is needed.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3264464

Track record

14 reports on NMRA

Performance horizon

3 of 6 bullish or bearish reports moved the stock their way by T+5. Best: +77.33% at T+60 after the Aug 20, 2026 report. 5 of 6 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $0.3760 Now $0.3700 −1.60% settles Nov 24
  2. Nov 16, 2026today Press Release Neutral 4/10 Entry $0.4206 Now $0.3700 −12.03% settles Nov 23
  3. Oct 30, 202617d ago 8-K Bearish 7/10 Entry $0.4957 to $0.4859 Now $0.3700 +25.36% ▲ +1.98% +2.06% vs SPY
  4. Sep 22, 20267w ago Institutional Cluster Neutral 3/10 Entry $0.7785 to $0.6776 Now $0.3700 −52.47% ▼ −12.96% −11.77% vs SPY
  5. Aug 20, 202612w ago 144 Bearish 5/10 Entry $1.63 to $1.39 Now $0.3700 +77.30% ▲ +14.72% +15.20% vs SPY
  6. Aug 17, 202613w ago 144 Bearish 5/10 Entry $1.64 to $1.50 Now $0.3700 +77.44% ▲ +8.54% +8.34% vs SPY
  7. Aug 14, 202613w ago 8-K Neutral 4/10 No price data
  8. Aug 14, 202613w ago Press Release Neutral 4/10 Entry $1.60 to $1.63 Now $0.3700 −76.87% ▲ +1.88% +3.24% vs SPY
  9. Jul 27, 202616w ago 8-K Bullish 5/10 Entry $1.66 to $1.61 Now $0.3700 −77.71% ▼ −3.01% −4.09% vs SPY
  10. Jul 27, 202616w ago Press Release Bullish 7/10 Entry $1.66 to $1.61 Now $0.3700 −77.71% ▼ −3.01% −4.09% vs SPY
Showing 10 of 14

US Market Status

Market Closed · Opens in 6h 38m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 30, 2026